The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

被引：0
|
作者：
C. J. Currie
C. D. Poole
E. A. M. Gale
机构：
[1] Cardiff University,School of Medicine
[2] The Pharma Research Centre,Department of Epidemiology
[3] Cardiff MediCentre,Diabetes and Metabolism, School of Medicine
[4] Pharmatelligence,undefined
[5] Bristol University,undefined
来源：
Diabetologia | 2009年 / 52卷
关键词：
Cancer; Insulin; Insulin analogues; Metformin; Sulfonylureas; Survival; Type 2 diabetes;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1766 / 1777
页数：11
相关论文
共 50 条
  • [41] Time-Varying Risk for Breast Cancer Following Initiation of Glucose-Lowering Therapy in Women with Type 2 Diabetes: Exploring Detection Bias
    Bowker, Samantha L.
    Lin, Mu
    Eurich, Dean T.
    Johnson, Jeffrey A.
    CANADIAN JOURNAL OF DIABETES, 2017, 41 (02) : 204 - 210
  • [42] Association between Glucose-lowering Treatments and Risk of Diabetic Retinopathy in People with Type 2 Diabetes: A Nationwide Cohort Study
    Jensen, Jakob Hasselstrom
    Vestergaard, Peter
    Jensen, Morten Hasselstrom
    CURRENT DRUG SAFETY, 2024, 19 (02) : 236 - 243
  • [43] The relationship between intensification of blood glucose-lowering therapies, health status and quality of life in type 2 diabetes: The Fremantle Diabetes Study Phase II
    Davis, Timothy M. E.
    Bruce, David G.
    Curtis, Bradley H.
    Barraclough, Helen
    Davis, Wendy A.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2018, 142 : 294 - 302
  • [44] Impact of cancer on adherence to glucose-lowering drug treatment in individuals with diabetes
    Marjolein M. J. Zanders
    Harm R. Haak
    Myrthe P. P. van Herk-Sukel
    Lonneke V. van de Poll-Franse
    Jeffrey A. Johnson
    Diabetologia, 2015, 58 : 951 - 960
  • [45] Progression of glucose-lowering diabetes therapy in TECOS
    Bethel, M. Angelyn
    Engel, Samuel S.
    Stevens, Susanna R.
    Lokhnygina, Yuliya
    Ding, Jie
    Josse, Robert G.
    Alvarsson, Michael
    Hramiak, Irene
    Green, Jennifer B.
    Peterson, Eric D.
    Holman, Rury R.
    ENDOCRINOLOGY DIABETES & METABOLISM, 2019, 2 (01)
  • [46] Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure
    Bowker, S. L.
    Yasui, Y.
    Veugelers, P.
    Johnson, J. A.
    DIABETOLOGIA, 2010, 53 (08) : 1631 - 1637
  • [47] A modern approach to glucose-lowering therapy in frail older people with type 2 diabetes mellitus
    Abdelhafiz, Ahmed H.
    Pennells, Daniel
    Sinclair, Alan J.
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2022, 17 (02) : 95 - 98
  • [48] Cardiovascular prevention in type 2 diabetes mellitus patients: the role of oral glucose-lowering agents
    Anselmino, Matteo
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2009, 23 (06) : 427 - 433
  • [49] Creative use of novel glucose-lowering drugs for type 2 diabetes: where will we head in the next 50 years?
    Ahren, Bo
    DIABETOLOGIA, 2015, 58 (08) : 1740 - 1744
  • [50] Creative use of novel glucose-lowering drugs for type 2 diabetes: where will we head in the next 50 years?
    Bo Ahrén
    Diabetologia, 2015, 58 : 1740 - 1744
12345